Comparative Pharmacology
Head-to-head clinical analysis: DOXERCALCIFEROL versus PARICALCITOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXERCALCIFEROL versus PARICALCITOL.
DOXERCALCIFEROL vs PARICALCITOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxercalciferol is a synthetic vitamin D2 analog that undergoes hepatic conversion to its active metabolite, 1α,25-dihydroxyvitamin D2, which binds to the vitamin D receptor (VDR) in the parathyroid glands, reducing parathyroid hormone (PTH) synthesis and secretion. It also increases intestinal calcium and phosphate absorption and promotes bone mineralization.
Paricalcitol is a synthetic vitamin D analog that binds to the vitamin D receptor (VDR) in target tissues, including the parathyroid glands, kidneys, and intestines. It selectively activates VDR to suppress parathyroid hormone (PTH) secretion, reduce parathyroid cell proliferation, and modulate calcium and phosphate homeostasis with lower calcemic and phosphatemic effects compared to calcitriol.
0.5 mcg orally three times per week at each hemodialysis session; alternatively, 1 mcg orally three times per week. Intravenous: 0.5 mcg bolus three times per week at end of hemodialysis; titrate to target intact parathyroid hormone (iPTH) level.
0.04 to 0.1 mcg/kg intravenously bolus no more frequently than every other day during dialysis, or 1 to 4 mcg orally once daily.
MODERATE Risk
Clinical Note
moderateParicalcitol + Digoxin
"The risk or severity of adverse effects can be increased when Paricalcitol is combined with Digoxin."
Clinical Note
moderateParicalcitol + Hydrochlorothiazide
"Paricalcitol may increase the hypercalcemic activities of Hydrochlorothiazide."
Clinical Note
moderateDoxercalciferol + Hydrochlorothiazide
"Doxercalciferol may increase the hypercalcemic activities of Hydrochlorothiazide."
Clinical Note
moderateParicalcitol + Bendroflumethiazide
MODERATE Risk
Terminal elimination half-life is approximately 96 hours (range 48–168 hours) in patients with chronic kidney disease, reflecting slow release from adipose tissue and prolonged vitamin D receptor activation.
Terminal elimination half-life is approximately 5-7 hours in healthy subjects, but may be prolonged to 14-20 hours in patients with renal impairment.
Primarily fecal (biliary) elimination; renal excretion accounts for <2% of unchanged drug in urine.
Primarily fecal (74%) via hepatobiliary excretion; renal elimination accounts for approximately 16% as unchanged drug.
Category A/B
Category C
Vitamin D Analog
Vitamin D Analog
"Paricalcitol may increase the hypercalcemic activities of Bendroflumethiazide."